Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL987769 | 1.00 | TSHR (0.50) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL18890187 | 1.00 | TSHR (0.50) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL386937 | 1.00 | TSHR (0.50) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL7799597 | 1.00 | TSHR (0.50) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL10834271 | 1.00 | TSHR (0.50) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL55660 | 0.94 | TSHR (0.55) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL6728641 | 0.90 | TSHR (0.52) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL28138591 | 0.90 | MEN1 (0.53) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL23356752 | 0.89 | TSHR (0.68) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL23356849 | 0.89 | TSHR (0.68) | TSHRMAPK1MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12597635-B2 | Electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2026-04-07 | — | — | US | disclosed |
| US-12095081-B2 | Electrolytic solution and electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| US-20240014378-A1 | POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| CN-116918095-A | Positive electrode and electrochemical device | 株式会社村田制作所 | 2023-10-20 | — | — | CN | disclosed |
| US-20230223525-A1 | ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| CN-116250124-A | Electrochemical device | 株式会社村田制作所 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022209595-A1 | POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE | 株式会社村田製作所 | 2022-10-06 | — | — | WO | disclosed |
| CN-110407998-B | Composition for reducing aldehyde release, polyol product, polyurethane system, preparation method and application thereof | 奥斯佳材料科技(上海)有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3832772-A1 | ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE | Murata Manufacturing Co., Ltd. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210151803-A1 | ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-8956768-B2 | Nonaqueous electrolyte comprising one or more hydrofluoroethers and one or more non-fluoroethers, and a secondary cell containing the nonaqueous electrolyte | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2270917-B1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY CELL AND SECONDARY CELL COMPRISING THE SAME | ASAHI GLASS CO LTD (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20130101904-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2579378-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2013-04-10 | — | — | EP | disclosed |
| EP-2495797-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214073-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2450998-A1 | ELECTROLYTIC SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTIC SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120107701-A1 | ELECTROLYTE SOLUTION FOR CHARGEABLE DEVICE, ELECTROLYTE SOLUTION FOR LITHIUM ION SECONDARY BATTERY, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20110020700-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY CELL, AND SECONDARY CELL | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2270917-A1 | SECONDARY CELL NONAQUEOUS ELECTROLYTE AND SECONDARY CELL | Asahi Glass Company, Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12597635-B2 | Electrochemical device | CLCN2, HCN4, SLC26A3 | TSHR 1300/4885MAPK1 1413/4885MEN1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.